Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials.
We created our purpose-built European fill finish facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products.
Differing from most fill finish CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients in the US.
Our core manufacturing capability takes place within an MHRA-licensed facility, which enables our team to fill bulk volumes under 100 liters, including products that require aseptic liquid filling and lyophilization such as:
- Biologics including mAb’s, proteins, peptides and RNA
- Cytotoxic, cytostatic and high potent APIs including ADCs
- Small molecules
Regulatory compliance, technical capability and operational flexibility are core to Symbiosis’ offerings and direct access to the best people who deliver projects on time is what our clients demand and receive every day.
Since the company began, we have steadily grown with our sustainable business model. Our team, facilities and capabilities have continued to expand in-line with growing demands from clients in North America and Europe.
If you’re looking for a European fill finish CMO, contact us today.